From mice to men

GEMMs as trial patients for new NSCLC therapies

Sarah A. Hayes, Amanda L. Hudson, Stephen J. Clarke, Mark P. Molloy, Viive M. Howell*

*Corresponding author for this work

Research output: Contribution to journalReview article

12 Citations (Scopus)


Given the large socio-economic burden of cancer, there is an urgent need for in vivo animal cancer models that can provide a rationale for personalised therapeutic regimens that are translatable to the clinic. Recent developments in establishing mouse models that closely resemble human lung cancers involve the application of genetically engineered mouse models (GEMMs) for use in drug efficacy studies or to guide patient therapy. Here, we review recent applications of GEMMs in non-small cell lung cancer research for drug development and their potential in aiding biomarker discovery and understanding of biological mechanisms behind clinical outcomes and drug interactions.

Original languageEnglish
Pages (from-to)118-127
Number of pages10
JournalSeminars in Cell and Developmental Biology
Publication statusPublished - 2014

Fingerprint Dive into the research topics of 'From mice to men: GEMMs as trial patients for new NSCLC therapies'. Together they form a unique fingerprint.

  • Cite this